{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T12:32:29Z","timestamp":1794832349631,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118329","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:19:59Z","timestamp":1752592799000},"page":"118329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-5982","authenticated-orcid":false,"given":"Angela","family":"\u00c4bel\u00f6","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7348-5115","authenticated-orcid":false,"given":"John W.","family":"Smallridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4087-3650","authenticated-orcid":false,"given":"Robin","family":"von Rotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario A.","family":"Dornbierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5072-9674","authenticated-orcid":false,"given":"Klemens","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1313-2208","authenticated-orcid":false,"given":"Milan","family":"Scheidegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118329_bib1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0378-8741(84)90003-5","article-title":"Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and \u03b2-carboline constituents of Ayahuasca","volume":"10","author":"McKenna","year":"1984","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biopha.2025.118329_bib2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0378-8741(98)00168-8","article-title":"Pharmacokinetics of Hoasca alkaloids in healthy humans","volume":"65","author":"Callaway","year":"1999","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biopha.2025.118329_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/ph13110334","article-title":"Toxicokinetics and toxicodynamics of ayahuasca alkaloids N,N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine: clinical and forensic impact","volume":"13","author":"Brito-da-Costa","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2025.118329_bib4","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.biopha.2025.118329_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115886","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis","volume":"335","author":"Yao","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.biopha.2025.118329_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118329_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000438","article-title":"Adverse effects of ayahuasca: results from the global ayahuasca survey","volume":"2","author":"Bouso","year":"2022","journal-title":"PLoS Glob. Public Health"},{"key":"10.1016\/j.biopha.2025.118329_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/02791072.2020.1815911","article-title":"Chemical composition of traditional and analog ayahuasca","volume":"53","author":"Kaasik","year":"2021","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.biopha.2025.118329_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00018-024-05353-6","article-title":"Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors","volume":"81","author":"Egger","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.biopha.2025.118329_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117908","article-title":"Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: \u03b1 factorial dose-escalation study","volume":"184","author":"Egger","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2025.118329_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1302559","article-title":"Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects","volume":"14","author":"Aicher","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118329_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1246892","article-title":"Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine","volume":"14","author":"Dornbierer","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118329_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyaf001","article-title":"Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine\/harmine formulation in healthy participants: a randomized controlled trial","volume":"28","author":"Mueller","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2025.118329_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/02791072.2005.10399797","article-title":"Fast and slow metabolizers of Hoasca","volume":"37","author":"Callaway","year":"2005","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.biopha.2025.118329_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s13318-023-00822-y","article-title":"Pharmacokinetics of N,N-dimethyltryptamine in humans","volume":"48","author":"Good","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.biopha.2025.118329_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51974-4","article-title":"Neural correlates of the DMT experience assessed with multivariate EEG","volume":"9","author":"Timmermann","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118329_bib17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/psp4.12933","article-title":"N,N-dimethyltryptamine affects electroencephalography response in a concentration-dependent manner\u2014a pharmacokinetic\/pharmacodynamic analysis","volume":"12","author":"Eckern\u00e4s","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"10.1016\/j.biopha.2025.118329_bib18","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1111\/cts.13410","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine \u2013 Implications for dose considerations","volume":"15","author":"Eckern\u00e4s","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.biopha.2025.118329_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cpt.3459","article-title":"Harnessing pharmacogenomics in clinical research on psychedelic-assisted therapy","volume":"117","author":"Halman","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118329_bib20","series-title":"NONMEM User\u2019s Guides","author":"Beal","year":"2009"},{"key":"10.1016\/j.biopha.2025.118329_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.biopha.2025.118329_bib22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","article-title":"Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance","volume":"30","author":"Zhang","year":"2003","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.biopha.2025.118329_bib23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","article-title":"Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling","volume":"43","author":"Dosne","year":"2016","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.biopha.2025.118329_bib24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"Savic","year":"2007","journal-title":"J. Pharmcokinet. Pharmacodyn."},{"key":"10.1016\/j.biopha.2025.118329_bib25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41398-023-02477-4","article-title":"Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants","volume":"13","author":"Vogt","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118329_bib26","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41386-024-02041-8","article-title":"Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants","volume":"50","author":"Erne","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2025.118329_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1163\/156856003765764272","article-title":"Localization of monoamine oxidase A and B and semicarbazide-sensitive amine oxidase in human peripheral tissues","volume":"11","author":"Ramonet","year":"2003","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.biopha.2025.118329_bib28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s004410100361","article-title":"Cellular localization of monoamine oxidase A and B in human tissues outside of the central nervous system","volume":"304","author":"Rodr\u00edguez","year":"2001","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.biopha.2025.118329_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.102.047050","article-title":"Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic \u03b2-carboline alkaloids harmaline and harmine","volume":"305","author":"Yu","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.118329_bib30","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/dta.2028","article-title":"Interspecies metabolic diversity of harmaline and harmine in in vitro 11 mammalian liver microsomes","volume":"9","author":"Li","year":"2017","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.biopha.2025.118329_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.toxlet.2021.06.013","article-title":"Do. Nicotine stimulates CYP1A1 expression in human hepatocellular carcinoma cells via AP-1, NF-\u03baB, and AhR","volume":"349","author":"Ung","year":"2021","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.biopha.2025.118329_bib32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/00498254.2023.2278488","article-title":"N,N-dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an in vitro investigation","volume":"53","author":"Eckern\u00e4s","year":"2023","journal-title":"Xenobiotica"},{"key":"10.1016\/j.biopha.2025.118329_bib33","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00436-019-06210-3","article-title":"Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers","volume":"118","author":"Ariffin","year":"2019","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.biopha.2025.118329_bib34","article-title":"CYP2D6 overview: allele and phenotype frequencies","author":"Kane","year":"2025","journal-title":"Med. Genet. Summ."},{"key":"10.1016\/j.biopha.2025.118329_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41398-020-01129-1","article-title":"Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19","volume":"11","author":"Koopmans","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118329_bib36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41431-019-0480-8","article-title":"Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe","volume":"28","author":"Petrovi\u0107","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.biopha.2025.118329_bib37","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM, and COMT genotypes and select opioid therapy","volume":"110","author":"Crews","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118329_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2133\/dmpk.24.25","article-title":"Mechanistic basis of using body size and maturation to predict clearance in humans","volume":"24","author":"Anderson","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.biopha.2025.118329_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","article-title":"Human psychopharmacology of N,N-dimethyltryptamine","volume":"73","author":"Strassman","year":"1995","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2025.118329_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00213-014-3658-3","article-title":"The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice","volume":"232","author":"Carbonaro","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopha.2025.118329_bib41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2218949120","article-title":"Human brain effects of DMT assessed via EEG-fMRI","volume":"120","author":"Timmermann","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118329_bib42","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.35082","article-title":"Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor","volume":"7","author":"Preller","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.biopha.2025.118329_bib43","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/npp.2015.46","article-title":"Individual differences in impulsive action reflect variation in the cortical serotonin 5-HT2A receptor system","volume":"40","author":"Fink","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2025.118329_bib44","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1002\/hbm.25138","article-title":"Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels","volume":"41","author":"Spies","year":"2020","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.biopha.2025.118329_bib45","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1523\/JNEUROSCI.2852-09.2010","article-title":"A nonlinear relationship between cerebral serotonin transporter and 5-HT2A receptor binding: an in vivo molecular imaging study in humans","volume":"30","author":"Erritzoe","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118329_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/2050324516683325","article-title":"Constructing drug effects: a history of set and setting","volume":"3","author":"Hartogsohn","year":"2017","journal-title":"Drug Sci. Policy Law"},{"key":"10.1016\/j.biopha.2025.118329_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40262-024-01450-8","article-title":"Clinical pharmacokinetics of N,N-dimethyltryptamine (DMT): A systematic review and post-hoc analysis","volume":"64","author":"van der Heijden","year":"2025","journal-title":"Clin. Pharmacokinet."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:59:50Z","timestamp":1762311590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225005232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":47,"alternative-id":["S0753332225005232"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118329","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118329"}}